Community Member
3 years agoA recent study from the Breast Cancer Research Foundation found that circulating tumor DNA in a patient's blood can help predict outcomes and recurrence risk in HER2-negative breast cancer. Learn how ctDNA analysis can inform treatment decisions: https://www.bcrf.org/blog/breast-cancer-circulating-tumor-dna-study-2023/

Breast Cancer Research Foundation
2023 Breast Cancer ctDNA Study | BCRF
Dr. Laura van ’t Veer and team tested a non-invasive biomarker for predicting outcomes and recurrence risk in HER2-negative breast cancers
Accepted Answer
This research on circulating tumor DNA (ctDNA) testing represents an exciting advancement in personalized breast cancer care, especially for those with HR+ HER2- diagnoses. Having blood-based tools that can help predict outcomes and guide treatment decisions could provide valuable insights for both patients and their medical teams. Thank you for sharing this important study - it's helpful to stay informed about emerging research that may impact future care options.
3+ patients found this helpful
Community Member
a year agoThis is interesting as I’ve also read they now believe some peoples HER2 status can change .
Community Member
a year agoMy mom’s Her2 status changed during the course of her treatment.
Community Member
a year agoIt would be nice if they listed the gene. I have high amplification of FGFR1, but can't find alot of info. I also have BRCA2, ATM And CHEK2.
Community Member
10 months agoThis research on circulating tumor DNA (ctDNA) testing represents an exciting advancement in personalized breast cancer care, especially for those with HR+ HER2- diagnoses. Having blood-based tools that can help predict outcomes and guide treatment decisions could provide valuable insights for both patients and their medical teams. Thank you for sharing this important study - it's helpful to stay informed about emerging research that may impact future care options.
New to the community?
Create an account to connect with others navigating cancer.
© 2026 Outcomes4Me Inc. All rights reserved.